Opposing roles for complement component C5a in tumor progression and the tumor microenvironment

Journal of Immunology

Volumn 189, Issue 6, 2012, Pages 2985-2994

  Gunn, Lacey ^a   Ding, Chuanlin ^a   Liu, Min ^a   Ma, Yunfeng ^a   Qi, Chunjian ^a,b   Cai, Yihua ^a   Hu, Xiaoling ^a   Aggarwal, Deep ^a   Zhang, Huang Ge ^a   Yan, Jun ^a  

^a University of Louisville School of Medicine   (United States)

^b THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CD11B ANTIGEN; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; COMPLEMENT C5A; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, INNATE; LEUKOCYTES; LYMPHOMA; MICE; MICE, SCID; MICE, TRANSGENIC; OVARIAN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84866149234     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200846     Document Type: Article

References (43)

1. Huber-Lang, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12: 682-687. (Pubitemid 43865238)
2. Spendlove, I., J. M. Ramage, R. Bradley, C. Harris, and L. G. Durrant. 2006. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol. Immunother. 55: 987-995. (Pubitemid 43673590)
3. Yan, J., D. J. Allendorf, B. Li, R. Yan, R. Hansen, and R. Donev. 2008. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv. Exp. Med. Biol. 632: 159-174.
4. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
5. Ehrnthaller, C., A. Ignatius, F. Gebhard, and M. Huber-Lang. 2011. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol. Med. 17: 317-329.
6. Liu, J., L. Gunn, R. Hansen, and J. Yan. 2009. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp. Mol. Pathol. 86: 208-214.
7. Allendorf, D. J., J. Yan, G. D. Ross, R. D. Hansen, J. T. Baran, K. Subbarao, L. Wang, and B. Haribabu. 2005. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J. Immunol. 174: 7050-7056. (Pubitemid 40705670)
8. Li, B., D. J. Allendorf, R. Hansen, J. Marroquin, D. E. Cramer, C. L. Harris, and J. Yan. 2007. Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res. 67: 7421-7430. (Pubitemid 47206572)
9. Fuenmayor, J., K. Perez-Vazquez, D. Perez-Witzke, M. L. Penichet, and R. F. Montano. 2010. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg. Mol. Cancer Ther. 9: 2175-2185.
10. Kim, D. Y., C. B. Martin, S. N. Lee, and B. K. Martin. 2005. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle. Cancer Immunol. Immunother. 54: 1026-1037.
11. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.
12. Markiewski, M. M., and J. D. Lambris. 2009. Unwelcome complement. Cancer Res. 69: 6367-6370.
13. Markiewski, M. M., and J. D. Lambris. 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 30: 286-292.
14. Ostrand-Rosenberg, S. 2008. Cancer and complement. Nat. Biotechnol. 26: 1348-1349.
15. Li, B., D. J. Allendorf, R. Hansen, J. Marroquin, C. Ding, D. E. Cramer, and J. Yan. 2006. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J. Immunol. 177: 1661-1669. (Pubitemid 44092502)
16. Hicks, A. M., G. Riedlinger, M. C. Willingham, M. A. Alexander-Miller, C. Von Kap-Herr, M. J. Pettenati, A. M. Sanders, H. M. Weir, W. Du, J. Kim, et al. 2006. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc. Natl. Acad. Sci. USA 103: 7753-7758.
17. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
18. Nozawa, H., C. Chiu, and D. Hanahan. 2006. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. USA 103: 12493-12498. (Pubitemid 44267286)
19. Qian, B. Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder, and J. W. Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
20. Hashimoto, M., K. Hirota, H. Yoshitomi, S. Maeda, S. Teradaira, S. Akizuki, P. Prieto-Martin, T. Nomura, N. Sakaguchi, J. Köhl, et al. 2010. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 207: 1135-1143.
21. Fang, C., X. Zhang, T. Miwa, and W. C. Song. 2009. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 114: 1005-1015.
22. Fusakio, M. E., J. P. Mohammed, Y. Laumonnier, K. Hoebe, J. Köhl, and J. Mattner. 2011. C5a regulates NKT and NK cell functions in sepsis. J. Immunol. 187: 5805-5812.
23. Chan, C. J., D. M. Andrews, and M. J. Smyth. 2008. Can NK cells be a therapeutic target in human cancer? Eur. J. Immunol. 38: 2964-2968.
24. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2: 850-861. (Pubitemid 37328903)
25. Qian, B. Z., and J. W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
26. Ma, J., L. Liu, G. Che, N. Yu, F. Dai, and Z. You. 2010. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10: 112.
27. Solinas, G., S. Schiarea, M. Liguori, M. Fabbri, S. Pesce, L. Zammataro, F. Pasqualini, M. Nebuloni, C. Chiabrando, A. Mantovani, and P. Allavena. 2010. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 185: 642-652.
28. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
29. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207: 2439-2453.
30. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
31. Chen, W., T. Tang, J. Eastham-Anderson, D. Dunlap, B. Alicke, M. Nannini, S. Gould, R. Yauch, Z. Modrusan, K. J. DuPree, et al. 2011. Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc. Natl. Acad. Sci. USA 108: 9589-9594.
32. Liu, Y., Z. P. Han, S. S. Zhang, Y. Y. Jing, X. X. Bu, C. Y. Wang, K. Sun, G. C. Jiang, X. Zhao, R. Li, et al. 2011. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J. Biol. Chem. 286: 25007-25015.
33. Langer, H. F., K. J. Chung, V. V. Orlova, E. Y. Choi, S. Kaul, M. J. Kruhlak, M. Alatsatianos, R. A. Deangelis, P. A. Roche, P. Magotti, et al. 2010. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 116: 4395-4403.
34. Hanson, E. M., V. K. Clements, P. Sinha, D. Ilkovitch, and S. Ostrand-Rosenberg. 2009. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183: 937-944.
35. Ostrand-Rosenberg, S. 2010. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59: 1593-1600.
36. Carroll, M. C. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5: 981-986. (Pubitemid 41057714)
37. Peng, Q., K. Li, H. Patel, S. H. Sacks, and W. Zhou. 2006. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J. Immunol. 176: 3330-3341. (Pubitemid 43363979)
38. Strainic, M. G., J. Liu, D. Huang, F. An, P. N. Lalli, N. Muqim, V. S. Shapiro, G. R. Dubyak, P. S. Heeger, and M. E. Medof. 2008. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28: 425-435.
39. Lalli, P. N., M. G. Strainic, M. Yang, F. Lin, M. E. Medof, and P. S. Heeger. 2008. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112: 1759-1766.
40. Weaver, D. J., Jr., E. S. Reis, M. K. Pandey, G. Köhl, N. Harris, C. Gerard, and J. Köhl. 2010. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur. J. Immunol. 40: 710-721.
41. + T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J. Immunol. 179: 3178-3186.
42. + T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am. J. Transplant. 9: 1784-1795.
43. Ward, P. A. 2004. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4: 133-142. (Pubitemid 38209207)